

Attorney Docket No.: 2543-1-023CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Raymond A. Dwek et al.

EXAMINER: Daniel M. Sullivan, Ph.D.

SERIAL NO.: 10/758,247

ART UNIT: 1636

FILED : January 15, 2004

FOR : THERAPEUTIC COMPOSITIONS AND METHODS OF TREATING  
GLYCOLIPID STORAGE RELATED DISORDERS

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 21, 2007.

Carolyn Di Meglio  
(Name of Depositor)

[Signature] 8/21/07  
(Signature and Date)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Supplemental Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References **BB** and **BK** listed on the attached Supplemental Form PTO-1449. Enclosed please find check in the amount of \$180.00 in payment of this filing. However, should the Patent and Trademark Office determine additional fees are due, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

08/23/2007 HVUONG1 00000069 10758247


03 FC:1806

180.00 0P

Respectfully submitted,

[Signature]  
Sarah J. Fashena, Ph.D.  
Agent for Applicants  
Registration No. 57,600

KLAUBER & JACKSON LLC  
411 Hackensack Avenue  
Hackensack, New Jersey 07601  
(201) 487-5800  
Date: August 21, 2007



Form PTO-049 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2543-1-023CON
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT  (Third Supplemental Information Disclosure Statement)	SERIAL NO.	10/758,247
	APPLICANT	Raymond A. Dwek et al.
	FILING DATE	January 15, 2004
	GROUP	1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BB	Gopalan et al., Kinetic analysis of the interaction of alkyl glycosides with two human $\beta$ -glucosidases, Biochem J., 1989, 262:541-548
	BC	Gatt et al., Use of activators and inhibitors to define the properties of the active site of normal and Gaucher disease lysosomal beta-glucosidase, Enzyme, 1985, 33(2):109-19, (Abstract Only)
	BD	Grabowski et al., Human Acid $\beta$ -Glucosidase, The Journal of Biological Chemistry, 1986, 261:8263-8269
	BE	Grace et al., Analyses of Catalytic Activity and Inhibitor Binding of Human Acid $\beta$ -Glucosidase by Site-directed Mutagenesis, The Journal of Biological Chemistry, 1990, 265:6827-6835
	BF	Warren et al., The effects of <i>N</i> -hexyl- <i>O</i> -glucosyl sphingosine on normal cultured human fibroblasts: a chemical model for Gaucher's disease, Journal of Lipid Research, 1976, 17:132-138
	BG	Shafit-Zagardo et al., Human beta-glucosidase: inhibition by sulphates and purification by affinity chromatography on Dextran-sulphate-Sepharose, Biochim Biophys Acta, 1981 May 14, 659(1):7-14 (Abstract Only)

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2543-1-023CON
	SERIAL NO.	10/758,247
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT  (Third Supplemental Information Disclosure Statement)	APPLICANT	Raymond A. Dwek et al.
	FILING DATE	January 15, 2004
	GROUP	1636

	BH	Blonder et al., Effects of detergents and choline-containing phospholids on human spleen glucocerebrosidase, Biochim Biophys Acta, 1976 Apr 22, 431(1):45-53 (Abstract Only)
	BI	Saul et al., Castanospermine, a tetrahydroxylated alkaloid that inhibits beta-glucosidase and beta-glucocerebrosidase, Arch Biochem Biophys, 1983 Mar, 221(2):593-7 (Abstract Only)
	BJ	Sano et al., The inhibition of glucosylceramide $\beta$ -glucosidase and other acid hydrolases by nucleic acids, Biochem J., 1988, 254:297-300
	BK	Platt et al., Inhibitors of Glycosphingolipid Biosynthesis, Trends in Glycoscience and Glycotechnology, 1995, 7:495-511

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	